Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 39.94 -2.06% -0.84
IONS closed down 2.06 percent on Monday, April 19, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical IONS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.06%
New 52 Week Low Weakness -2.06%
Wide Bands Range Expansion -2.06%
Oversold Stochastic Weakness -2.06%
Older End-of-Day Signals for IONS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 15 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Down 2 % about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago
New 52 Week Low about 17 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ionis Pharmaceuticals, Inc. Description

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organ Systems Alcohol Diabetes Cancers Rare Diseases Drug Discovery Genetics Prostate Cancer Disorders Lipid Neurological Disorders Hepatitis B Multiple Sclerosis Obesity Dystrophy Cholesterol Steatohepatitis Hepatitis C Amyloid Hepatitis B Virus Hepatitis C Virus Huntington's Disease Myopathy Amyloidosis Angioedema Hereditary Angioedema Spinal Muscular Atrophy Treatment Of Diabetes Cardiomyopathy Dyslipidemia Hypercholesterolemia Acromegaly Cushing's Syndrome Myotonic Dystrophy Orphan Drugs Therapeutic Gene Modulation Antisense RNA Familial Amyloid Polyneuropathy Hepatitis C Virus Infection Mozy Ocular Disease Polyneuropathy Severe And Rare Diseases Apatorsen Hepatitis B Virus Infection Homozygous Familial Hypercholesterolemia Ionis Lipodystrophy Mixed Dyslipidemia Onemia TTR Amyloidosis

Is IONS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 64.37
52 Week Low 39.18
Average Volume 1,302,283
200-Day Moving Average 52.99
50-Day Moving Average 50.58
20-Day Moving Average 43.80
10-Day Moving Average 42.15
Average True Range 1.99
ADX 30.48
+DI 18.14
-DI 40.30
Chandelier Exit (Long, 3 ATRs ) 50.00
Chandelier Exit (Short, 3 ATRs ) 45.14
Upper Bollinger Band 50.49
Lower Bollinger Band 37.11
Percent B (%b) 0.21
BandWidth 30.56
MACD Line -2.94
MACD Signal Line -2.86
MACD Histogram -0.0818
Fundamentals Value
Market Cap 5.58 Billion
Num Shares 140 Million
EPS 0.52
Price-to-Earnings (P/E) Ratio 77.10
Price-to-Sales 7.67
Price-to-Book 5.15
PEG Ratio 25.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.55
Resistance 3 (R3) 42.59 41.75 42.12
Resistance 2 (R2) 41.75 41.09 41.74 41.97
Resistance 1 (R1) 40.85 40.68 40.43 40.81 41.82
Pivot Point 40.01 40.01 39.81 40.00 40.01
Support 1 (S1) 39.11 39.35 38.69 39.07 38.06
Support 2 (S2) 38.27 38.94 38.26 37.91
Support 3 (S3) 37.37 38.27 37.77
Support 4 (S4) 37.33